{"id":"W2008243627","doi":"10.1038/nrclinonc.2009.83","title":"Cetuximab, chemotherapy and KRAS status in mCRC","year":2009,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Cetuximab; Medicine; Bevacizumab; KRAS; Colorectal cancer; Chemotherapy; Oncology; Internal medicine; Panitumumab; Monoclonal antibody; Cancer; Antibody; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.001667566,0.0006655226,0.01048404,0.0001928945,0.00004686545,0.00001148159,0.0001544802,0.0026757,0.0001306186],"category_scores_gemma":[0.001599572,0.0003910502,0.001253904,0.0004951458,0.0002261328,0.00003240698,0.00009414922,0.00369398,0.00007229507],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007316797,"about_ca_system_score_gemma":0.001002293,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001459802,"about_ca_topic_score_gemma":0.0002035946,"domain_scores_codex":[0.9949259,0.0008777727,0.002492491,0.0009476503,0.000201068,0.0005551649],"domain_scores_gemma":[0.9967184,0.001472497,0.0009018711,0.0005026756,0.00007542003,0.0003291416],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001438279,0.0007549687,0.0003421934,0.005587297,0.0002750875,0.0002056161,0.00002088434,9.616886e-10,8.720791e-9,0.00005188335,0.009080171,0.9835381],"study_design_scores_gemma":[0.002973313,0.003311733,0.002113528,0.01178847,0.001816481,0.0001321839,0.000003610528,2.133617e-7,1.156251e-8,0.00006177652,0.9775057,0.000293],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001426645,0.9821415,4.062666e-7,0.001307167,0.0006356194,0.003269216,0.00001759628,0.00003196342,0.01258224],"genre_scores_gemma":[0.000005152787,0.9916033,0.001018056,0.005351647,0.0008457644,0.0002619806,0.00007650122,0.00004690567,0.0007906632],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9832451,"threshold_uncertainty_score":0.9998541,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1578366754923965,"score_gpt":0.553432103833239,"score_spread":0.3955954283408426,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}